Cathflo, the 2-mg t-PA—a fibrin-specific therapy*

• Limited systemic exposure.

Produced by recombinant DNA technology, Cathflo is a fibrin-specific t-PA*

Like naturally forming human t-PA, Cathflo acts specifically on fibrin-rich clots in an occluded catheter.

• Cathflo causes the conversion of plasminogen to plasmin
• Plasmin dissolves fibrin in a clot, which results in thrombotic breakdown
• With the clot dissolved, any residual debris can be aspirated from the catheter, and central venous access is restored
• With Cathflo, there is limited systemic exposure because it works by dwelling in the catheter in direct contact with the clot
• Because it has a short half-life, circulating plasma levels of Cathflo are not expected to reach pharmacologic concentrations, even if a small quantity enters the bloodstream

See how Cathflo breaks down the clot

If you do not have RealPlayer installed or wish to update your existing player, please download the free basic player.